ArticleDigestive diseases and sciences1999
Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue.
Article in Digestive diseases and sciences, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 40 citations in OpenAlex.
- Dopamine D2 receptor polymorphisms and adenoma recurrence in the Polyp Prevention Trial.International journal of cancer · 2009Trial
- Therapeutic strategies for colorectal cancer: antitumor efficacy of dopamine D2 receptor antagonists.Toxicological research · 2024Review
- Correlation between Neurotransmitters (Dopamine, Epinephrine, Norepinephrine, Serotonin), Prognostic Nutritional Index, Glasgow Prognostic Score, Systemic Inflammatory Response Markers, and TNM Staging in a Cohort of Colorectal Neuroendocrine Tumor Patients.International journal of molecular sciences · 2024Article
- Research progress on the roles of dopamine and dopamine receptors in digestive system diseases.Journal of cellular and molecular medicine · 2024Review
- Dopamine receptors gene overexpression in the microenvironment of invasive gastric cancer and its potential implications.Molecular biology reports · 2023Article
- Understanding the role of dopamine in cancer: past, present and future.Carcinogenesis · 2022Review
- The Inhibitory Effect of Selected DCells · 2022Article
- Pathophysiologic Role of Neurotransmitters in Digestive Diseases.Frontiers in physiology · 2021Review
- Risk Factors for Recurrent Colorectal Polyps.Gut and liver · 2020Review
- Triggering Neurotransmitters Secretion from Single Cells by X-ray Nanobeam Irradiation.Nano letters · 2020Article
- Emerging role of dopamine in neovascularization of pheochromocytoma and paraganglioma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Review
- Potential Roles of Peripheral Dopamine in Tumor Immunity.Journal of Cancer · 2017Review
- Aripiprazole an atypical antipsychotic protects against ethanol induced gastric ulcers in rats.International journal of clinical and experimental medicine · 2014Article
- Epigenetic repression of the dopamine receptor D4 in pediatric tumors of the central nervous system.Journal of neuro-oncology · 2014Article
- Biogenic amines serotonin and dopamine regulate cholangiocyte hyperplastic and neoplastic growth.World journal of gastrointestinal pathophysiology · 2010Article
- Increased local dopamine secretion has growth-promoting effects in cholangiocarcinoma.International journal of cancer · 2010Article
- Transforming growth factor-beta1 (TGF-beta1) and acetylcholine (ACh) alter nitric oxide (NO) and interleukin-1beta (IL-1beta) secretion in human colon adenocarcinoma cells.In vitro cellular & developmental biology. Animal · 2009Article
- DRD2/DARPP-32 expression correlates with lymph node metastasis and tumor progression in patients with esophageal squamous cell carcinoma.World journal of surgery · 2006Article
- Role of dopamine in malignant tumor growth.Endocrine · 2000Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As an important enteric neurotransmitter, the role of dopamine as a mitotic inhibitor as well as a protective factor of epithelial cells of stomach and colon indicates its significance in malignant growth of gastrointestinal tract. Our previous results have shown significant alteration of dopamine receptors in human malignant stomach tissues. The present experiments, therefore, evaluate DA content, its receptor expression, and its second-messenger cAMP in human malignant colon tissues to evaluate its role. Results demonstrate a significant decrease of dopamine content, its receptor expression, and its second-messenger cAMP in malignant tissues of human colon. These results may provide insight into the role of dopamine as an enteric neurotransmitter on malignant growth of human colon and may also suggest a therapeutic approach targeting dopamine receptors and its signal transduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.